Aprea Therapeutics Inc.

About Aprea Therapeutics Inc.

Aprea Therapeutics is a biopharmaceutical company dedicated to developing novel DNA Damage Response (DDR) targeted cancer therapeutics. Their mission is to revolutionize cancer treatment through precision medicine, focusing on therapies that match treatments to specific genetic mutations to maximize effectiveness and minimize side effects, with the goal of benefiting millions of cancer patients.

Products & Services

DDR-Targeted Therapeutics:Small molecule inhibitors designed to exploit genetic mutations in cancer, aiming to increase selectivity, maximize clinical activity, and minimize toxicity by destroying cancer cells while sparing healthy tissue.

Pipeline:A robust portfolio exploring multiple targets to enhance the chances of success in developing cancer treatments, broadening the scope of therapeutic options.

Clinical Trials:Ongoing trials advancing DDR-targeted therapies towards market availability, with the aim of benefiting a large number of cancer patients.

Specialties

DNA Damage Response (DDR) Targeted Therapeutics Precision Medicine Small Molecule Inhibitors Cancer Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 5600000 MR: - FA: approximately $5.6 million FAN: 5600000	D: 2026-01-29 FD: 2026-01-29	2 investors
2	RT: Private Placement T: - FT: Private Placement	A: 3100000 MR: - FA: 3.1 million FAN: 3100000	D: 2025-12-09 FD: 2025-12-09	2 investors
3	RT: Private Placement T: - FT: Private Placement	A: 34000000 MR: - FA: up to $34.0 million FAN: 34000000	D: 2024-03-11 FD: 2024-03-11	6 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 5500000 MR: - FA: $5.5 million FAN: 5500000	D: 2023-02-27 FD: 2023-02-27	1 investors
5	RT: Underwritten Public Offering of Common Stock T: - FT: Underwritten Public Offering of Common Stock	A: 5500000 MR: - FA: $5.5 million FAN: 5500000	D: 2023-02-22 FD: 2023-02-22	1 investors
6	RT: SBIR Grant T: - FT: SBIR Grant	A: 1996571 MR: - FA: $1,996,571 FAN: 1996571	D: 2023-02-15 FD: 2023-02-15	1 investors

Private Placement Latest

2026-01-29

$5.6M

2 investors (Pro only)

Private Placement 2025-12-09

$3.1M

Private Placement 2024-03-11

$34.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

O

Oren Gilad

President and Chief Executive Officer

J

John P. Hamill

Senior Vice President and Chief Financial Officer

M

Mike Carleton

Translational Medicine Advisor

P

Philippe Pultar

Senior Medical Advisor

Z

Ze'ev Weiss

Chief Business Advisor

B

Brian Wiley

Senior Vice President of Corporate Development & Strategy

View 11 more team members with Pro

Unlock Full Team Directory

Recent News